A detailed history of Spire Wealth Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Spire Wealth Management holds 198 shares of NBIX stock, worth $24,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
198
Previous 198 -0.0%
Holding current value
$24,850
Previous $27,000 18.52%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$130.86 - $143.19 $8,113 - $8,877
62 Added 45.59%
198 $27,000
Q1 2024

Apr 24, 2024

SELL
$130.4 - $143.74 $2,216 - $2,443
-17 Reduced 11.11%
136 $18,000
Q4 2023

Feb 06, 2024

BUY
$106.07 - $132.76 $8,485 - $10,620
80 Added 109.59%
153 $20,000
Q3 2023

Nov 08, 2023

SELL
$94.02 - $117.1 $29,710 - $37,003
-316 Reduced 81.23%
73 $8,000
Q2 2023

Aug 09, 2023

BUY
$89.53 - $104.87 $895 - $1,048
10 Added 2.64%
389 $36,000
Q1 2023

May 09, 2023

BUY
$94.11 - $123.02 $23,903 - $31,247
254 Added 203.2%
379 $38,000
Q4 2022

Feb 03, 2023

BUY
$106.72 - $127.06 $1,600 - $1,905
15 Added 13.64%
125 $15,000
Q3 2022

Nov 07, 2022

SELL
$92.03 - $107.81 $460 - $539
-5 Reduced 4.35%
110 $12,000
Q2 2022

Jul 22, 2022

BUY
$75.79 - $100.07 $378 - $500
5 Added 4.55%
115 $11,000
Q1 2022

Apr 18, 2022

SELL
$72.45 - $94.81 $1,231 - $1,611
-17 Reduced 13.39%
110 $10,000
Q4 2021

Jan 14, 2022

SELL
$79.65 - $106.22 $14,575 - $19,438
-183 Reduced 59.03%
127 $11,000
Q2 2021

Jul 26, 2021

SELL
$89.43 - $102.27 $25,308 - $28,942
-283 Reduced 47.72%
310 $30,000
Q1 2021

May 21, 2021

BUY
$87.57 - $119.4 $51,929 - $70,804
593 New
593 $58,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.